Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02791334 · ClinicalTrials.gov registry record · Phase 1
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
A Phase 1 study of Pancreatic Cancer and Solid Tumor, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
- 14
- Study locations
NCT02791334: Completed Phase 1 study of Pancreatic Cancer and Solid Tumor, sponsored by Eli Lilly and Company.
NCT02791334 is a Phase 1 study of Pancreatic Cancer and Solid Tumor that has completed, run by Eli Lilly and Company. The registered enrollment target is 164 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (58% lower). The trial reports 14 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02791334, a Phase 1 study of Pancreatic Cancer and Solid Tumor, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
- 14
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
Conditions Studied
Interventions
- DRUG Abemaciclib
- DRUG Ramucirumab
- DRUG Merestinib
- DRUG LY3300054
- DRUG LY3321367
Study Locations (14)
Other
- Cliniques Universitaires Saint-Luc - Brussels
- Universitair Ziekenhuis Antwerpen - Edegem
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest - Bordeaux
- Gustave Roussy - Villejuif
- Seoul National University Hospital - Seoul
- Severance Hospital Yonsei University Health System - Seoul
- Hospital Universitario Fundación Jiménez Díaz - Madrid
- Hospital Madrid Norte Sanchinarro - Madrid
- National Cheng Kung University Hospital - Tainan
- National Taiwan University Hospital - Taipei
Texas
- University of Texas MD Anderson Cancer Center - Houston
- The START Center for Cancer Care - San Antonio
Tennessee
- Tennessee Oncology PLLC - Nashville
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2016-06-29 |
| Est. Completion | 2024-06-27 |
| Phase | Phase 1 |
What the finished NCT02791334 record still lists
NCT02791334 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (58% lower).
The record links to 5 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Abemaciclib is the first listed.
NCT02791334 lists 14 locations in 4 states (Other, Texas, Tennessee).
Frequently Asked Questions
What is clinical trial NCT02791334 about?
NCT02791334 is a clinical study titled "A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors". The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.
What is the current status of trial NCT02791334?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2016-06-29. Estimated completion is 2024-06-27.
What conditions does trial NCT02791334 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Solid Tumor, Cutaneous Melanoma, Microsatellite Instability-High (MSI-H) Solid Tumors, Breast Cancer (HR+HER2-).
What interventions are being tested in trial NCT02791334?
The interventions under investigation include: Abemaciclib (DRUG), Ramucirumab (DRUG), Merestinib (DRUG), LY3300054 (DRUG), LY3321367 (DRUG).
Who is sponsoring clinical trial NCT02791334?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02791334 being conducted?
This trial has 14 study locations across Tennessee, Texas, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02791334's enrollment target sits among peer trials
164 76th of 278 higher than 203 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI